Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Asthmatic Agents | 5 | 2024 | 565 | 1.570 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2022 | 79 | 0.810 |
Why?
|
| Personnel, Hospital | 2 | 2021 | 285 | 0.810 |
Why?
|
| Immunoglobulin M | 2 | 2021 | 1529 | 0.660 |
Why?
|
| Asthma | 5 | 2024 | 6167 | 0.650 |
Why?
|
| Renal Replacement Therapy | 1 | 2021 | 281 | 0.640 |
Why?
|
| Respiratory Function Tests | 1 | 2024 | 1684 | 0.640 |
Why?
|
| Low Back Pain | 2 | 2023 | 979 | 0.560 |
Why?
|
| Biological Products | 2 | 2023 | 914 | 0.550 |
Why?
|
| Neuralgia | 1 | 2022 | 597 | 0.510 |
Why?
|
| Antibodies, Viral | 2 | 2021 | 3145 | 0.420 |
Why?
|
| Thailand | 3 | 2023 | 289 | 0.420 |
Why?
|
| Immunoglobulin G | 2 | 2021 | 4546 | 0.410 |
Why?
|
| Kidney Failure, Chronic | 2 | 2022 | 2469 | 0.400 |
Why?
|
| Peritoneal Dialysis | 2 | 2022 | 157 | 0.360 |
Why?
|
| Seroepidemiologic Studies | 2 | 2021 | 393 | 0.340 |
Why?
|
| Immunotherapy | 1 | 2022 | 4637 | 0.270 |
Why?
|
| Chemokine CCL17 | 1 | 2024 | 26 | 0.240 |
Why?
|
| Meta-Analysis as Topic | 3 | 2023 | 1375 | 0.220 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2023 | 62 | 0.210 |
Why?
|
| Chemokine CXCL10 | 1 | 2024 | 316 | 0.210 |
Why?
|
| Galactogogues | 1 | 2022 | 1 | 0.210 |
Why?
|
| Interleukin-13 | 1 | 2024 | 371 | 0.200 |
Why?
|
| Glomerulonephritis | 1 | 2023 | 337 | 0.190 |
Why?
|
| Zygapophyseal Joint | 1 | 2023 | 128 | 0.190 |
Why?
|
| Cannabinoids | 1 | 2023 | 173 | 0.190 |
Why?
|
| Peritonitis | 1 | 2022 | 370 | 0.170 |
Why?
|
| Plasma Exchange | 1 | 2020 | 158 | 0.170 |
Why?
|
| Lupus Nephritis | 1 | 2023 | 318 | 0.170 |
Why?
|
| Lactation | 1 | 2022 | 395 | 0.170 |
Why?
|
| Nephrotic Syndrome | 1 | 2023 | 391 | 0.170 |
Why?
|
| Eosinophils | 1 | 2024 | 946 | 0.160 |
Why?
|
| Hospitals, Community | 1 | 2021 | 367 | 0.160 |
Why?
|
| Mycoses | 1 | 2022 | 387 | 0.160 |
Why?
|
| Probiotics | 1 | 2022 | 377 | 0.160 |
Why?
|
| Immunoglobulin E | 1 | 2024 | 1493 | 0.150 |
Why?
|
| Milk, Human | 1 | 2022 | 484 | 0.140 |
Why?
|
| Nephrology | 1 | 2021 | 263 | 0.140 |
Why?
|
| Cannabis | 1 | 2023 | 436 | 0.140 |
Why?
|
| Neuromyelitis Optica | 1 | 2020 | 259 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 785 | 0.130 |
Why?
|
| Propensity Score | 1 | 2022 | 1918 | 0.120 |
Why?
|
| Bayes Theorem | 1 | 2022 | 2325 | 0.120 |
Why?
|
| Dermatology | 1 | 2023 | 914 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 2023 | 2093 | 0.100 |
Why?
|
| Humans | 20 | 2024 | 760261 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 2160 | 0.090 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2021 | 1905 | 0.090 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 2623 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2021 | 2003 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 2296 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 1935 | 0.080 |
Why?
|
| Health Personnel | 1 | 2021 | 3310 | 0.070 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3737 | 0.070 |
Why?
|
| Prevalence | 2 | 2021 | 15687 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2022 | 8018 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 15827 | 0.060 |
Why?
|
| Lung | 1 | 2024 | 9989 | 0.060 |
Why?
|
| Adult | 7 | 2024 | 219847 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2024 | 41317 | 0.060 |
Why?
|
| Prebiotics | 1 | 2022 | 41 | 0.050 |
Why?
|
| Myostatin | 1 | 2023 | 127 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 64947 | 0.050 |
Why?
|
| Domperidone | 1 | 2022 | 24 | 0.050 |
Why?
|
| Injections, Intra-Articular | 1 | 2023 | 280 | 0.050 |
Why?
|
| Indonesia | 1 | 2021 | 128 | 0.050 |
Why?
|
| Hospitals, University | 1 | 2023 | 568 | 0.050 |
Why?
|
| Middle Aged | 4 | 2024 | 220175 | 0.050 |
Why?
|
| Female | 7 | 2024 | 391011 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 25928 | 0.040 |
Why?
|
| Male | 6 | 2024 | 359413 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2024 | 1600 | 0.040 |
Why?
|
| Stroke | 1 | 2022 | 9945 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2023 | 80301 | 0.040 |
Why?
|
| Fungi | 1 | 2022 | 338 | 0.040 |
Why?
|
| Sputum | 1 | 2021 | 503 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 2020 | 384 | 0.040 |
Why?
|
| Mucin-1 | 1 | 2023 | 539 | 0.040 |
Why?
|
| Placebo Effect | 1 | 2022 | 511 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2022 | 746 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 1455 | 0.030 |
Why?
|
| Catheterization | 1 | 2021 | 1432 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2022 | 1168 | 0.030 |
Why?
|
| Aged | 2 | 2024 | 168995 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2022 | 1386 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 1933 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2024 | 4357 | 0.030 |
Why?
|
| Biopsy | 1 | 2023 | 6775 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2020 | 2635 | 0.020 |
Why?
|
| Radiography | 1 | 2021 | 6965 | 0.020 |
Why?
|
| Proteomics | 1 | 2023 | 3810 | 0.020 |
Why?
|
| Kidney | 1 | 2023 | 7072 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 9196 | 0.020 |
Why?
|
| Young Adult | 2 | 2022 | 58673 | 0.020 |
Why?
|
| Incidence | 1 | 2023 | 21378 | 0.010 |
Why?
|
| Adolescent | 2 | 2022 | 87747 | 0.010 |
Why?
|
| Quality of Life | 1 | 2023 | 13300 | 0.010 |
Why?
|
| Pregnancy | 1 | 2022 | 29725 | 0.010 |
Why?
|
| Child | 1 | 2023 | 79758 | 0.010 |
Why?
|
Concepts
(99)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(9)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_